IDEXX Laboratories, Inc. (IDXX) Q4 FY25 Earnings Call

Management expects 7%-9% organic growth despite approximately 2% U.S. clinical-visit declines.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-03
Length60 minutes
EPS$3.08
EPS consensus$2.93
Revenue$1.1B

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY25

All IDXX earnings ยท Back to IDXX overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.